Login to Your Account

Allergy adcom gives unanimous thumbs up to Grastek tablet

By Catherine Shaffer
Staff Writer

Friday, December 13, 2013
In day two of the FDA’s Allergenic Products Advisory Committee meeting, it reviewed Alk-Abello A/S and Merck and Co. Inc.’s Grastek sublingual tablet. Members agreed unanimously that available data support efficacy of Grastek for treatment of Timothy grass pollen-induced allergic rhinitis in patients 5 to 65 years and that adrenaline auto-injectors must be made available for patients at home.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription